Studies have shown that neoadjuvant nivolumab may provide long-term benefits for people with non-small cell lung cancer.

Published Date: 17 Feb 2023

BACKGROUND: NSCLC is the most common and important cause of cancer worldwide. Assessment: The patient...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

HER3 Antibody Drug Conjugate Shows Promise in NSCLC

2.

Novel Agent for Chronic GVHD Wins FDA Approval

3.

Cancer mortality continuing to decline, says report

4.

Increased detection of adenomas may reduce colon cancer risk after colonoscopy in FIT-based screening.

5.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot